Cigna Group 8-K

What Happened
The Cigna Group (CI) filed an 8-K reporting the results of its Annual Meeting of Shareholders held April 22, 2026. Of 263,660,761 shares outstanding, 237,225,441 (89.97%) were represented. All twelve director nominees were elected to one-year terms. Shareholders also voted on executive compensation (advisory), ratification of PricewaterhouseCoopers LLP as auditor, and a shareholder proposal on the right to act by written consent.

Key Details

• Shares represented: 237,225,441 of 263,660,761 outstanding (89.97%). Broker non-votes: 17,604,610 on director, compensation and written-consent votes.
• Directors elected (examples of vote totals): David M. Cordani — 213,026,538 For / 6,415,867 Against; Mark B. McClellan, M.D., Ph.D. — 218,991,478 For / 443,519 Against. Some nominees received notable opposition (e.g., Eric J. Foss: 207,618,924 For / 11,810,097 Against).
• Advisory vote on executive compensation (say-on-pay): 201,746,941 For / 17,359,954 Against / 513,936 Abstentions.
• Auditor ratification: PricewaterhouseCoopers LLP ratified with 216,061,458 For / 21,030,077 Against / 133,906 Abstentions.
• Shareholder proposal to allow shareholders to act by written consent was defeated: 104,982,574 For / 114,173,793 Against / 464,464 Abstentions (broker non-votes: 17,604,610).

Why It Matters
The meeting confirmed the current board slate and approved the company’s executive compensation in a non-binding vote, providing continuity for governance and strategy. The auditor was ratified but drew more than 21 million votes against, which may signal some investor concerns. The defeat of the written-consent proposal means shareholders do not gain that additional mechanism to act outside of formal meetings. These governance votes are important signals about investor sentiment and can affect engagement between Cigna and its shareholders.